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Abstract
Background Heart failure is heterogeneous in aetiology, pathophysiology, and presentation. Despite this diversity, clinical 
trials of patients hospitalized for HF deal with this problem as a single entity, which may be one reason for repeated failures.
Methods The first EuroHeart Failure Survey screened consecutive deaths and discharges of patients with suspected heart 
failure during 2000–2001. Patients were sorted into seven mutually exclusive hierarchical presentations: (1) with cardiac 
arrest/ventricular arrhythmia; (2) with acute coronary syndrome; (3) with rapid atrial fibrillation; (4) with acute breathless-
ness; (5) with other symptoms/signs such as peripheral oedema; (6) with stable symptoms; and (7) others in whom the 
contribution of HF to admission was not clear.
Results The 10,701 patients enrolled were classified into the above seven presentations as follows: 260 (2%), 560 (5%), 799 
(8%), 2479 (24%), 1040 (10%), 703 (7%), and 4691 (45%) for which index-admission mortality was 26%, 20%, 10%, 8%, 
6%, 6%, and 4%, respectively. Compared to those in group 7, the hazard ratios for death during the index admission were 4.9 
(p ≤ 0.001), 4.0 (p < 0.001), 2.2 (p < 0.001), 2.1 (p < 0.001), 1.4 (p < 0.04) and 1.4 (p = 0.04), respectively. These differences 
were no longer statistically significant by 12 weeks.
Conclusion There is great diversity in the presentation of heart failure that is associated with very different short-term out-
comes. Only a minority of hospitalizations associated with suspected heart failure are associated with acute breathlessness. 
This should be taken into account in the design of future clinical trials.
Keywords Acute heart failure · Presentation of heart failure · Mortality
Introduction
Acute heart failure (AHF) is heterogeneous in its aetiology, 
pathophysiology, and presentation. European Society of 
Cardiology (ESC) 2008 guidelines classify AHF into six 
different clinical presentations, amongst which there is con-
siderable overlap. Most events are classified as decompen-
sated chronic heart failure and the rest as acute pulmonary 
oedema, cardiogenic shock, right heart failure or associated 
with severe hypertension or acute coronary syndrome [1]. 
It is clear that AHF is not a discrete diagnosis but a col-
lection of different clinical syndromes that require clini-
cal intervention with varying degrees of urgency [2, 3]. A 
patient with severe breathlessness at rest in acute pulmo-
nary oedema is a medical emergency requiring immediate 
investigation and treatment [4, 5]. A patient presenting with 
increasing exertional breathlessness and worsening periph-
eral oedema might be considered sub-acute and requiring 
 * Ahmad Shoaib 
 Ahmad.shoaib@hyms.ac.uk; drahmadshoaib@yahoo.com
1 Keele Cardiovascular Research Group, Institute of Applied 
Clinical Sciences and Centre for Prognosis Research, Keele 
University, Stoke on Trent, UK
2 Department of Academic Cardiology, University of Hull, 
Kingston upon Hull, UK
3 Postgraduate Medical School, University of Hertfordshire, 
Hertfordshire, UK
4 Department of Cardiology, University of Pierre and Marie 
Curie Paris VI, La Pitié-Salpêtrière Hospital, Paris, France
5 Robertson Centre for Biostatistics, University of Glasgow 
and National Heart and Lung Institute, Imperial College 
London, London, UK
 Clinical Research in Cardiology
1 3
treatment within hours or days rather than minutes [6, 7]. 
If the target and purpose of therapy is diverse then trials 
that treat all AHF as a single entity are likely to fail. Better 
characterization of the heterogeneous clinical presentation 
of AHF might help inform the design of future clinical trials 
that target the unmet needs of specific presentations of AHF 
[8–10]. Accordingly, we obtained information from the First 
EuroHeart Failure Survey (EHFS-1) that enrolled more than 
10,000 patients from 115 hospitals over a 6 week snapshot to 
describe the outcome of patients with different presentations 
of patients hospitalized for or with heart failure [11, 12].
Methods
EHFS-1 screened consecutive deaths and discharges dur-
ing 2000–2001 primarily from medical wards over a 6 week 
period in 115 hospitals from 24 countries in Europe, to iden-
tify patients with known or suspected heat failure (HF). The 
design and implementation of the survey have been pub-
lished in detail previously [13]. Each hospital recorded con-
secutive deaths and discharges from medical, cardiology, 
cardiac surgery, and geriatric medicine wards over a period 
of 6 weeks [11]. Surgical, gynaecology, ophthalmology, and 
renal wards were excluded. Records were screened to iden-
tify if the patient fulfilled one or more of the following four 
criteria:
1. A clinical diagnosis of HF, primary or contributory, dur-
ing the index admission.
2. A diagnosis of HF recorded in the hospital records at any 
time during the previous 3 years.
3. Administration of loop diuretics during the 24 h prior 
to death or discharge during the index admission, other 
than for end-stage renal disease.
4. Administration of treatment for HF or for ventricular 
dysfunction within the 24 h prior to death or discharge.
Patients who fulfilled one or more inclusion criteria were 
further classified by investigators according to clinical pres-
entation, aetiology, final diagnosis and whether, in the inves-
tigators opinion, HF was the primary diagnosis, a secondary 
diagnosis complicating or prolonging hospital admission, 
an incidental finding (e.g. patients who were admitted for 
another reason and whose admission was not complicated 
or prolonged by HF) or diagnostically uncertain (mostly 
patients taking loop diuretics for no obvious reason).
Classification of presentation
Presentation at hospital admission was classified hierarchi-
cally (patients belonging to a preceding class/group could 
not belong to any subsequent class/group) as follows:
1. Cardiac arrest, ventricular tachycardia, or fibrillation or 
cardiogenic shock.
2. Acute coronary syndrome (ACS).
3. Atrial fibrillation (AF) with a rapid ventricular response 
(> 120/min).
4. Severe shortness of breath at rest.
5. Other symptoms of HF, such as worsening peripheral 
oedema.
6. Stable symptoms.
7. Contribution of HF to admission uncertain.
Detailed information regarding events contributing to 
the current admission, cardiovascular and non-cardiovas-
cular comorbid illnesses, and clinical investigations during 
admission and therapy at discharge or 24 h prior to death 
were recorded by investigators as well as deaths during the 
index hospital admission and deaths and readmissions within 
12 weeks after discharge.
For most patients, left ventricular systolic dysfunction 
(LVSD) was not measured formally but assessed in a semi-
quantitative fashion. For guidance, a left ventricular ejection 
fraction (LVEF) of < 40% was considered to reflect moderate-
to-severe LVSD.
Continuous data are summarized by the median and 
25th/75th percentiles; categorical data by percentages. As 
time-to-event data were not recorded after discharge, prognos-
tic models for all-cause mortality were developed using Logis-
tic regression. Prognostic models were developed using k-fold 
cross validation [14]. This procedure splits the data randomly 
into k partitions. For each partition, it fits the specified model 
using the other k − 1 groups, and uses the resulting param-
eters to predict the dependent variable in the unused group [15, 
16]. We arbitrarily choose k as 25 (hence 25-fold cross valida-
tion). We started with 50 clinically relevant variables and then 
selected those variables in the final model that remained sig-
nificant for at least 70% of cross validations. The significance 
level to remain in the model was initially set to 0.05 for each 
model. From the logistic regression models, receiver operating 
characteristic (ROC) curves were plotted as sensitivity versus 
1 − specificity. An area under the ROC curve was calculated 
using methods outlined in Hanley and McMeil [17]. The area 
under the ROC represents the probability of classifying an 
individual as dead/alive. An area under the ROC curve of 1.0 
means perfect classification, while an area of 0.5 means that 
classification is no better than chance. The Stata 13 statistical 
computer package was used to analyse the data.
Results
HF was the primary diagnosis in 4234 (40%) patients, a sec-
ondary diagnosis in 1772 (17%), and was considered not to 
have caused or complicated the index admission in 4695 
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(44%) [18]. Of the 6006 patients in whom HF was thought 
to cause or complicate admission, the most common pres-
entation was severe breathlessness at rest (n = 2479; 42% of 
such patients) (Table 1).
The age and sex distribution was broadly similar for the 
various patient presentations, but patients presenting with 
a cardiac arrest or in shock and those with stable symp-
toms were slightly younger and were more likely to be men 
(Table 1). Apart from those admitted with a cardiac arrest/
shock or ACS, about one-third of patients had a prior his-
tory of myocardial infarction. AF was present in 34–43% 
of patients, not including those patients with rapid AF as 
their primary presentation. For each group, apart from 
ACS, > 50% had been treated with loop diuretics prior to 
admission and prescription at discharge ranged from 72 to 
88% amongst groups. When echocardiographic informa-
tion was available (6096 patients), moderate-to-severe left 
ventricular systolic dysfunction (LVSD) was reported in 
41–69% of cases and moderate-to-severe mitral regurgita-
tion in 25–42% (Table 1). Even when the contribution of 
HF to admission was uncertain, 41% were reported to have 
moderate-to-severe LVSD, 25% moderate-to-severe mitral 
regurgitation, 61% cardiomegaly or pulmonary congestion 
on a chest X-ray, 74% were prescribed loop diuretics, 60% 
an ACE inhibitor or angiotensin receptor blocker, and 38% 
a beta-blocker (Table 2), making a diagnosis of heart failure 
likely in many cases.
Mortality during the index admission was higher for those 
presenting with a ventricular arrhythmia, cardiac arrest or 
shock (26%), or an ACS (20%) (Table 2). The group for 
which HF made an uncertain contribution to admission 
had a lower in-patient mortality (4%). Median length of 
stay varied from 8 to 11 days amongst groups. Of 10,701 
patients, 12 weeks follow-up data were available for 9779 
(91%). Mortality in the 12 weeks after discharge varied little 
amongst groups, ranging from 5 to 8% (Table 2). Most of 
these deaths were ascribed to cardiovascular causes or infec-
tion; few were ascribed to cancer. Within 12 weeks, 19–29% 
of patients had been re-admitted, mostly for cardiovascular 
problems of which HF was the main reason in about half of 
admissions except for the group with an uncertain contribu-
tion of HF to the index admission.
On multivariable analysis, MI during the index admis-
sion, a history of VT/VF, a history of stroke, left ventricular 
dilatation, and serum creatinine concentration were associ-
ated with mortality on the index admission (Table 3). The 
area under receiver operating characteristics (ROC) curve 
was 0.74. A second model, using a less rigorous p value of 
0.1 for selection, identified four more variables; age, sex, 
medical history of hypertension and infection. The area 
under ROC curve in the second model was 0.78 (Fig. 1). 
We used Akaike’s information criterion (AIC) and Bayes-
ian information criterion (BIC) to compare the two models. 
A smaller AIC/BIC ratio in model 2 (0.96 in model 1 and 
0.95 in model 2) and a large difference of BIC between mod-
els (67) indicated the superiority of model 2 [19, 20]. In 
a final logistic regression model after adjusting for all rel-
evant covariates, mortality remained higher in groups 1–6 
as compared to group 7 (uncertain contribution of HF to 
admission).
For mortality between discharge and 12 weeks, a history 
of valve repair was the only variable which was significant 
using p < 0.05 for model selection in 25 cross validations and 
the model discrimination was poor (ROC 0.55). If p < 0.1 
was used, a history of diabetes, LVSD, left ventricle dilata-
tion, and history of angina during index admission provided 
additional information but this improved the ROC only to 
0.57. In the logistic regression model, only Group 2 (ACS) 
(OR 1.73, p = 0.03, CI 1.07–2.95) and Group 4 (severe 
breathlessness) (OR 1.61, p = 0.002, CI 1.18–2.18) added 
to model prediction (OR compared to Group 7).
In a multivariable analysis investigating variables asso-
ciated with all-cause readmission during the 12-week fol-
low-up period, a history of hypertension, LVSD, and aor-
tic stenosis were identified in 25 cross validations using 
p < 0.05 for model selection. In the logistic regression, only 
Group 6 added to the model with OR of 1.69 (p < 0.001, CI 
1.34–2.12) compared to Group 7. However, the area under 
the ROC curve was only 0.55. When p < 0.1 was used to 
select variables from 25 cross validations, a history of infec-
tion, a history of valve replacement, and mitral regurgitation 
were identified that improved the ROC to 0.57 and again, 
only Group 6 added to the logistic regression model (OR of 
1.77, p < 0.001, CI 1.40–2.24).
Discussion
EHFS-1 was designed to investigate the overall burden of 
heart failure from a hospital perspective and not just a nar-
rowly defined group of patients admitted with heart failure 
as a primary diagnosis and managed by cardiologists [3, 
21]. The survey emphasizes the heterogeneity of patients 
hospitalized with suspected HF [22, 23]. Fewer than half 
of patients presented with severe breathlessness at rest and 
yet this has been the main focus of trials of AHF until now. 
Patients presenting primarily with increasing oedema appear 
to be a common, but neglected group of patients [24]; recent 
post-hoc analyses suggests that such patients might account 
for the response observed to agents for AHF such as sere-
laxin [25].
It is now fashionable to highlight the lack of progress 
in the treatment of AHF, as opposed to the huge progress 
made in the last 25 years for chronic HF [2, 26–28]. Unfor-
tunately, the only Class 1, level of evidence A recommenda-
tion for the management of AHF in the ESC 2012 guidelines 
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Table 1  Clinical characteristics
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7
Presentation Arrest/VT/Shock ACS Rapid AF ASOB Other/oedema Stable Uncertain
Numbers (%) 260 (2%) 560 (5%) 799 (8%) 2479 (24%) 1040 (10%) 703 (7%) 4695 (44%)
Age in years 
(IQR)
 69 (61–76) 73 (66–81) 75 (66–82) 74 (66–80) 72 (62–79) 66 (56–76) 73 (64–80)
Women (%) 90 (35%) 240 (43%) 424 (53%) 1185 (48%) 457 (44%) 258 (37%) 2293 (49%)
BMI (kg/m2) 
(IQR)
26 (24–29) 26 (24–29) 26 (23–30) 26 (23–29) 26 (24–30) 26 (24–30) 27 (24–30)
Prior HF admis-
sion (%)
89 (38%) 92 (35%) 322 (40%) 1136 (46%) 429 (41%) 320 (46%) 708 (15%)
Loop diuretics 
prior to admis-
sion (%)
131 (59%) 184 (36%) 408 (55%) 1651 (71%) 665 (70%) 530 (79%) 2395 (58%)
Loop diuretics 
prior to death or 
discharge (%)
211 (82%) 428 (77%) 667 (84%) 2177 (88%) 748 (72%) 539 (77%) 3455 (74%)
ACS—this admis-
sion
87 (34%) 493 (89%) 13 (2%) 43 (2%) 9 (1%) 10 (1%) 413 (9%)
MI (anytime) 146 (56%) 530 (95%) 183 (23%) 782 (32%) 335 (32%) 213 (31%) 1746 (37%)
Any IHD (ACS/
Revasc)
DCM 48 (19%) 32 (6%) 88 (11%) 380 (15%) 128 (12%) 181 (26%) 336 (7%)
Valve replace-
ment/repair
12 (5%) 14 (3%) 62 (8%) 130 (5%) 67 (6%) 59 (8%) 290 (6%)
AF (%) 111 (43%) 188 (34%) 765 (96%) 1006 (41%) 415 (40%) 239 (34%) 1738 (37%)
Prior H/O VT/VF 148 (58%) 77 (14%) 62 (8%) 134 (5%) 72 (7%) 74 (11%) 296 (6%)
Pacemaker 41 (16%) 31 (6%) 51 (6%) 219 (9%) 96 (9%) 81 (12%) 347 (7%)
ICD 29 (11%) 4 (1%) 1 (0.1%) 22 (1%) 17 (2%) 17 (2%) 60 (1%)
H/O hypertension 132 (52%) 329 (60%) 398 (50%) 1377 (56%) 550 (53%) 347 (50%) 2452 (53%)
Disabling stroke 17 (7%) 53 (10%) 45 (6%) 199 (8%) 111 (11%) 64 (9%) 438 (9%)
Minor stroke/TIA 26 (10%) 50 (9%) 70 (9%) 230 (9%) 87 (8%) 65 (9%) 539 (12%)
H/O renal dysf 72 (28%) 124 (22%) 145 (18%) 554 (22%) 193 (19%) 131 (19%) 593 (13%)
H/O resp. disease 63 (25%) 147 (27%) 289 (36%) 985 (40%) 297 (29%) 166 (24%) 1392 (30%)
Diabetes mellitus 56 (22%) 147 (26%) 171 (22%) 749 (30%) 279 (27%) 197 (28%) 1178 (25%)
H/O PE 11 (4%) 15 (3%) 29 (4%) 92 (4%) 37 (4%) 17 (2%) 145 (3%)
Clinical investigations
 Echo data avail-
able
177 376 513 1562 591 498 2339
 Moderate/
severe LVSD 
(ejection frac-
tion < 40%)
122 (69%) 240 (64%) 245 (48%) 840 (54%) 346 (59%) 317 (64%) 951 (41%)
 Moderate/severe 
LV dilatation
72 (41%) 78 (21%) 129 (25%) 514 (33%) 236 (40%) 202 (41%) 462 (20%)
Moderate/severe 
LA dilatation
59 (33%) 82 (22%) 194 (38%) 605 (39%) 247 (42%) 195 (39%) 574 (25%)
 Moderate/severe 
mitral regurgi-
tation
53 (30%) 100 (27%) 192 (37%) 559 (36%) 247 (42%) 180 (36%) 574 (25%)
 Moderate/severe 
aortic stenosis
7 (4%) 20 (5%) 39 (8%) 157 (10%) 62 (10%) 43 (9%) 163 (7%)
 Haemoglobin 
(g/dl) (IQR)
12.5 (11–14.2) 12.7 (11.2–13.9) 12.7 (1.1–14.2) 12.7 (11.3–14) 13.3 (11.8–14.5) 13.1 (1.5–14.7) 12.9 (11.3–14.2)
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is thrombo-embolism prophylaxis, but it is reduced to Class 
1, level of evidence B in ESC 2016 acute and chronic HF 
guidelines [29, 30]. In the most recent ESC guidelines 
(2016), no treatment was given a Class 1, level of evidence 
A recommendation for the management of AHF. There are 
many possible reasons for lack of progress in AHF [31]. 
The interventions studied may be truly ineffective or study 
design may have been inadequate [32, 33]. However, the het-
erogeneity of the patient population probably plays a major 
role. More precise patient selection, timing of intervention 
and targeting of therapy in clinical trials could reap large 
dividends [34]. More precise targeting does not necessar-
ily mean more restrictive inclusion criteria. For instance, if 
congestion and peripheral oedema, which usually develops 
over several weeks, is the primary treatment target then there 
is little point in trying to enrol patients within a few hours 
of admission, which is logistically difficult from a research 
perspective and greatly reduces recruitment. Peripheral 
oedema often persists for many days after initiating treat-
ment, allowing time for a new intervention to be introduced 
and its effects to become apparent. However, for patients 
with severe breathlessness due to pulmonary oedema, the 
onset is often abrupt; delaying intervention even for a few 
minutes may not be acceptable, and symptoms may have 
largely resolved within a few hours [2, 35]. There is only a 
small window of opportunity to show that a new intervention 
accelerates the improvement in symptoms. Whether health 
services would pay for a treatment that shortens the time to 
symptom relief by a few minutes is uncertain. Short-term 
treatments have not yet been shown to reduce the risk of 
longer term relapse or death.
Historically, the spectacular success in managing acute 
myocardial infarction (MI) was made possible by the 
development of coronary care units and the segregation of 
patients into ST elevation MI (STEMI) and non-ST elevation 
MI (NSTEMI) [36–38]. The same may be true for AHF not 
only in terms of their presentation, but also their underly-
ing left ventricular phenotype and atrial rhythm and where 
they are managed [30, 39]. Most trials of AHF have enrolled 
a mixture of patients presenting with severe acute-onset 
breathlessness at rest (pulmonary oedema) and others with 
sub-acute worsening of peripheral congestion who are not 
breathless sitting upright at rest, but have orthopnoea and are 
breathless on minor exertion. The median time to enrolment 
in trials of AHF, with one exception, has never been less 
than 6 h, by which time most patients with acute pulmonary 
oedema have responded to a combination of diuretics and 
oxygen and have only residual symptoms [2, 40]. The one 
Table 1  (continued)
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7
 Sodium 
(mmol/l) 
(IQR)
139 (135–142) 139 (136–142) 139 (136–142) 139 (136–142) 140 (137–142) 139 (136–142) 139 (136–142)
 Potassium 
(mmol/l) 
(IQR)
4.2 (3.8–4.6) 4.2 (3.8–4.6) 4.2 (3.9–4.6) 4.2 (3.9–4.6) 4.4 (4–4.8) 4.3 (4–4.7) 4.2 (3.9–4.6)
 Urea mmol/l 
(IQR)
12.9 (6.9–20.7) 10.7 (6.8–17) 10.4 (7.1–17.5) 11.8 (7.5–18.6) 9.4 (6.6–15) 10.5 (6.9–17.1) 8.9 (6.2–14.5)
 Creatinine 
(μmol/l)
(IQR)
124 (99–168) 106 (88–137) 106 (85–133) 106 (88–138) 106 (88–134) 106 (88–135) 101 (83–126)
 eGFR 30–60 ml/
min
 eGFR < 30 ml/
min
 Cholesterol 
most recent 
(mmol/l) 
(IQR)
5.1 (4–5.8) 5.1 (4.3–6) 4.7 (3.8–5.6) 4.9 (4–5.8) 4.9 (3.9–5.9) 5.1 (4.1–5.9) 5.1 (4.3–5.9)
 Chest X-ray: 
cardiomegaly/
pulmonary 
congestion
205 (94%) 392 (79%) 618 (86%) 1938 (88%) 717 (79%) 457 (76%) 2281 (61%)
HF heart failure, ACS acute coronary syndrome, AF atrial fibrillation, ASOB acute shortness of breath, Asymp. LVD asymptomatic left ventricle 
dysfunction, BMI body mass index, MI myocardial infarction, USA unstable angina, PCI percutaneous coronary intervention, CABG coronary 
artery bypass grafting, DCM dilated cardiomyopathy, SVT supraventricular tachycardia, VT ventricle tachycardia, VF ventricle fibrillation, TIA 
transient ischaemic attack, DM diabetes mellitus, PE pulmonary embolism, IQR interquartile range, LVEDD left ventricle end diastolic diameter, 
LVESD left ventricle end systolic diameter, LV left ventricle, LA left atrium
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Table 2  Drugs at discharge or 24 h prior to death and mortality
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7
Presentation Arrest/VT/shock ACS Rapid AF ASOB Other/oedema Stable Uncertain
Numbers (%)a 260 (2%) 560 (5%) 799 (8%) 2479 (24%) 1040 (10%) 703 (7%) 4695 (44%)
Spironolactone 61 (23%) 94 (17%) 203 (25%) 693 (28%) 351 (34%) 230 (33%) 540 (12%)
Furosemide 202 (78%) 436 (78%) 663 (83%) 2121 (86%) 774 (74%) 511 (73%) 3327 (71%)
Bumetanide 7 (3%) 7 (1%) 26 (3%) 97 (4%) 19 (2%) 12 (2%) 110 (2%)
Torasemide 14 (5%) 19 (3%) 38 (5%) 93 (4%) 30 (3%) 31 (4%) 140 (3%)
Metolazone 0 2 (0.4%) 11 (1%) 61 (2%) 16 (2%) 4 (1%) 21 (0.5%)
Thiazide diuretic 33 (13%) 41 (7%) 69 (9%) 219 (9%) 198 (19%) 96 (14%) 397 (8%)
ACEI 158 (61%) 399 (71%) 494 (62%) 1655 (67%) 735 (71%) 496 (71%) 2577 (55%)
ARB 7 (3%) 18 (3%) 28 (4%) 114 (5%) 47 (5%) 51 (7%) 213 (5%)
Nitrate 106 (41%) 316 (56%) 269 (34%) 1137 (46%) 525 (50%) 258 (37%) 2005 (43%)
CCB 30 (12%) 119 (21%) 178 (22%) 483 (19%) 184 (18%) 107 (15%) 1131 (24%)
Beta blockers 115 (44%) 309 (55%) 256 (32%) 676 (27%) 433 (42%) 288 (41%) 1790 (38%)
Digoxin 87 (33%) 140 (25%) 501 (63%) 1059 (43%) 469 (45%) 296 (42%) 1227 (26%)
Antiarrhythmic 
drugs
85 (33%) 96 (17%) 244 (31%) 300 (12%) 104 (10%) 127 (18%) 599 (13%)
Lipid lowering 
drugs
38 (15%) 147 (26%) 83 (10%) 420 (17%) 192 (18%) 159 (23%) 1097 (23%)
Mortality and length of stay during index admission
 Deaths 67 (26%) 114 (20%) 80 (10%) 201 (8%) 65 (6%) 41 (6%) 189 (4%)
 HR compared 
to class 7 
(uni-variable 
analysis)
4.86 (p ≤ 0.001, 
CI 3.57–6.6)
3.95 (p ≤ 0.001, 
CI 3.1–5)
2.22 (p ≤ 0.001, 
CI 1.7–2.9)
2.09 (p ≤ 0.001, 
CI 1.70–2.56)
1.36 (p = 0.04, 
CI 1.02–1.81)
1.44 (p = 0.04, 
CI 1.02–2.02)
Events contributing to death (proportion deaths)
 MI (%) 32 (47%) 98 (86%) 5 (6%) 11 (5%) 4 (6%) 3 (7%) 31 (16%)
 Worsening HF 45 (67%) 81 (71%) 60 (75%) 167 (83%) 52 (80%) 21 (51%) 35 (18%)
 Renal dysfunc-
tion
20 (30%) 33 (29%) 18 (23%) 54 (27%) 19 (29%) 10 (24%) 21 (11%)
 Ventricular 
arrhythmia
18 (27%) 21 (18%) 14 (18%) 18 (9%) 3 (5%) 3 (7%) 13 (7%)
 Atrial arrhyth-
mia
5 (7%) 15 (13%) 30 (38%) 14 (7%) 5 (8%) 4 (10%) 8 (4%)
 Infection 13 (5%) 18 (16%) 26 (33%) 65 (32%) 31 (48%) 14 (34%) 57 (30%)
 Stroke 3 (5%) 5 (4%) 2 (3%) 10 (5%) 10 (15%) 6 (15%) 32 (1%)
 Cancer 0 2 (2%) 5 (6%) 16 (8%) 2 (3%) 2 (5%) 30 (16%)
 Other 11 (16%) 13 (11%) 22 (28%) 45 (22%) 12 (18%) 10 (24%) 72 (38%)
 LoS-index 
admis-
sion (days) 
(median/IQR)
9 (4–16) 11 (7–18) 10 (6–15) 8 (5–13) 10 (5–17) 8 (3–14) 8 (4–13)
Mortality and readmission within 12 weeks after discharge
 Number at  risk* 193 446 719 2278 975 662 4506
Deaths after 
discharge
12 (6%) 36 (8%) 47 (7%) 175 (8%) 63 (6%) 41 (6%) 229 (5%)
 Unadjusted OR 
compared to 
class 7
1.18 (p = 0.58, 
CI 0.64–2.15)
1.56 (p = 0.02, 
1.08–2.25)
1.26 (p = 0.17, 
CI 0.91–1.75)
1.46 (p ≤ 0.001, 
CI 1.19–1.79)
1.14 (p = 0.37, 
CI 0.86–1.53)
1.18 (p = 0.35, 
CI 0.84–1.68)
Events contributing to death (proportion deaths)
 MI (%) 1 (8%) 10 (28%) 4 (9%) 12 (7%) 5 (8%) 2 (5%) 25 (11%)
 Worsening HF 
(%)
3 (25%) 9 (26%) 10 (21%) 68 (39%) 25 (40%) 17 (41%) 50 (22%)
 Renal dysf. (%) 0 2 (6%) 3 (6%) 19 (11%) 3 (5%) 6 (15%) 12 (6%)
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exception is the 3CPO study that enrolled patients with acute 
pulmonary oedema with heart and respiratory rates of 114 
and 33, respectively, within a few hours of presentation [41].
Not unsurprisingly, patients presenting with cardiogenic 
shock, VT/VF, and ACS had a much worse in-hospital 
prognosis, but subsequent to discharge their prognosis, 
both in terms of readmissions and death, was rather similar 
to patients with other presentations. Clearly, these patients 
require urgent measures to correct the haemodynamic dis-
turbance and to limit myocardial damage at the time of pres-
entation. The short-term prognosis of patients with AHF 
reported in epidemiological studies will depend greatly 
on whether such patients are included. HF as a second-
ary, rather than primary, diagnosis may have a much worse 
Table 2  (continued)
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7
 Arrhythmia (%) 1 (8%) 3 (9%) 2 (4%) 7 (4%) 3 (5%) 3 (7%) 7 (3%)
 Infection (%) 0 3 (9%) 6 (13%) 14 (8%) 8 (12%) 4 (10%) 40 (17%)
 Stroke 0 1 (3%) 8 (17%) 10 (6%) 4 (6%) 3 (7%) 19 (8%)
 Cancer 0 1 (3%) 3 (6%) 11 (6%) 6 (9%) 3 (7%) 28 (12%)
 Other 1 (8%) 7 (23%) 16 (34%) 32 (18%) 7 (11%) 5 (12%) 63 (28%)
Readmission within 12 weeks after discharge
 Number at  risk* 193 446 719 2278 975 662 4506
 All cause 43 (22%) 109 (24%) 166 (23%) 557 (24%) 189 (19%) 192 (29%) 980 (22%)
 Due to CV 
cause
33 (17%) 85 (19%) 131 (18%) 421 (18%) 155 (16%) 150 (23%) 580 (13%)
 Due to heart 
failure
20 (10%) 45 (10%) 73 (10%) 298 (13%) 98 (10%) 98 (15%) 240 (5%)
HF heart failure, ACS acute coronary syndrome, AF atrial fibrillation, ASOB acute shortness of breath, ACI angiotensin converting enzyme 
inhibitor, ARB angiotensin receptor blockers, LOS length of stay, MI myocardial infarction, IQR interquartile range, CV cardiovascular
a Data from 9779 patients were available for the 12-week follow-up period
Table 3  Logistic regression model for mortality during index admission
AUC area under curve, MI myocardial infarction, VT ventricle tachycardia, VF ventricle fibrillation, H/O history of, LV left ventricle</bib>
a Variables only included in model 2
Model 1
AUC 0.74
Model 2
AUC 0.78
Odds ratio as com-
pare to class 7
p value 95% Confidence interval Odds ratio as com-
pare to class 7
p value 95% 
Confidence 
interval
Group 1 4.29 < 0.001 2.38–7.96 4.18 < 0.001 2.2–8.1
Group 2 3.58 < 0.001 1.97–6.51 4.08 < 0.001 2.14–7.79
Group 3 4.34 < 0.001 2.60–7.25 4.09 < 0.001 2.39–7.05
Group 4 3.54 < 0.001 2.33–5.39 3.27 < 0.001 2.10–5.09
Group 5 2.93 < 0.001 1.73–4.96 3.39 < 0.001 1.94–5.95
Group 6 2.24 0.009 1.23–4.08 2.90 0.001 1.54–5.48
Agea – – – 1.03 < 0.001 1.01–1.04
Sexa – – – 0.86 0.36 0.64–1.17
MI this admission 2.61 < 0.001 1.58–4.31 2.52 < 0.001 1.47–4.35
VT/VF (anytime) 2.85 < 0.001 2.02–4.02 3.10 < 0.001 2.15–4.49
H/O  hypertensiona – – – 0.93 0.62 0.70–1.24
Stroke (anytime) 2.08 < 0.001 1.39–3.13 1.62 0.03 1.04–2.52
H/O  infectiona (during 
this admission)
– 3.37 < 0.001 2.52–4.50
LV dilatation 0.95 0.73 0.71–1.27
Creatinine 1.003 0.012 1.002–1.004 1.01 0.04 1.001–1.02
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short-term outcome, but few trials target such patients [18]. 
These findings highlight that HF is not a distinct diagnosis, 
but rather, a collection of clinical conditions with a great 
variety of underlying causes and clinical features, which fall 
under one umbrella term that is generally associated with 
a poor outcome. Targeting the therapeutic approach more 
accurately at specific patient subsets, presentations, aetiolo-
gies, and pathophysiologies and precipitating factors may 
yield greater benefit than a more generalised approach as 
is usual in current clinical trials. However, post-discharge 
outcome was rather similar regardless of presentation, even 
when it was unclear whether HF had precipitated or com-
plicated the admission. Clinical trials often exclude patients 
who do not fulfil robust criteria for a diagnosis of HF but 
who, nonetheless, almost certainly have this diagnosis and 
also have a poor prognosis for whom either further investiga-
tion and better treatment is required [42].
Patient heterogeneity amongst patients presenting with 
AHF is a fundamental problem when designing and per-
forming clinical trials. More accurate patient characteriza-
tion for right treatment on right target is most crucial for 
success in clinical step for designs of new clinical trials and 
clinical practice. Clinical presentation, precipitating factors, 
underlying cardiac phenotype and aetiology of cardiac dys-
function might each be used to classify patients with the 
AHF and select them for trials. These episodes are main 
areas to be considered for better categorization of these 
patients. Preferably, these areas should be clearly identified 
before randomization to a new therapy. For example, patients 
presenting with pulmonary oedema due to ACS are likely to 
benefit from different treatments from those presenting with 
severe peripheral oedema and atrial fibrillation. Accurate 
classification requires a basic set of information including 
a medical history and physical examination, haematology 
and biochemistry profile, oxygen saturation, chest X-ray, 
an electrocardiogram, and an echocardiogram. However, 
urgent access to echocardiography is often problematic due 
to a lack of skilled personnel available either at unsociable 
hours or available on medical wards within a few hours or 
sometimes even days, if at all. Up skilling the medical work-
force to provide at least basic echocardiography quickly and 
routinely should improve the management.
Limitations
EHFS-1 was conducted in 2000-01, but, until now, there 
have been no innovations in therapy for AHF and recent tri-
als suggest that the 12 week mortality of AHF has changed 
little in the past 15 years [16, 43, 44]. We developed mutu-
ally exclusive categories of patients but of course; in reality, 
some patients will belong to more than one class. However, 
in most such clinical situations, one presentation domi-
nates. Attempting to avoid falling into the trap of capturing 
data on only narrowly defined ‘cardiological’ heart failure 
may have caused some confusion and inconsistent answers 
for our international group of investigators, especially for 
patients who were taking loop diuretics, but who had not 
been diagnosed with heart failure. However, it is impossible 
to assess the quality of care with respect to investigation 
if only patients who already have a definitive diagnosis of 
heart failure are included. Many patients hospitalized with 
a diagnosis or features suspicious of HF were admitted pri-
marily for another reason. Most had features to suggest that 
they did indeed have HF and these patients had a high mor-
bidity and mortality subsequent to discharge. This group 
of patients has lower in-patient mortality but only slightly 
lower rates of readmission and death subsequent to discharge 
compared to other groups, although their rates of readmis-
sion for worsening heart failure and of cardiovascular deaths 
were substantially lower.
A major limitation of this survey was the failure to spe-
cifically ask about peripheral oedema. We assume that when 
peripheral oedema was the major presentation, these will 
have been classified as ‘other’. However, many patients pre-
senting with oedema will have had breathlessness on mild 
exertion or even at rest and may have been classified as pre-
senting with breathlessness.
Conclusion
Acute heart failure is a collection of syndromes with differ-
ent clinical presentations, precipitating factors, underlying 
aetiology, and pathophysiology that may affect the clinical 
course, prognosis, and response to treatment. A common 
feature of AHF is poor outcomes and the unmet clinical need 
Fig. 1  Comparison of two logistic regression models to assess mor-
tality during index admission by ROC curves. ROC receiver operator 
characteristic
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is still great. Focussing on specific presentations, such as 
acute pulmonary oedema, worsening peripheral oedema, or 
rapid AF, that may differ in their pathophysiology and treat-
ment goals might succeed, where the current efforts have 
so far failed.
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